Klotho Neurosciences, Inc. (KLTO) Stock Analysis & Investment Frameworks
Klotho Neurosciences, Inc. (KLTO) stock analysis on Invetso. Review Klotho Neurosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Klotho Neurosciences, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Klotho Neurosciences, Inc. Key Financial Metrics
- Market Cap: $20.08M
- Revenue: $N/A
- ROE: -108.82%
- ROIC: -25.34%
- Dividend Yield: N/A
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.